nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Estropipate—osteoporosis	0.0789	0.181	CbGbCtD
Pimecrolimus—CYP3A4—Calcitriol—osteoporosis	0.0789	0.181	CbGbCtD
Pimecrolimus—CYP3A4—Ergocalciferol—osteoporosis	0.0631	0.145	CbGbCtD
Pimecrolimus—CYP3A4—Raloxifene—osteoporosis	0.0527	0.121	CbGbCtD
Pimecrolimus—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0509	0.117	CbGbCtD
Pimecrolimus—CYP3A4—Cholecalciferol—osteoporosis	0.0407	0.0934	CbGbCtD
Pimecrolimus—CYP3A4—Conjugated Estrogens—osteoporosis	0.0373	0.0858	CbGbCtD
Pimecrolimus—CYP3A4—Estradiol—osteoporosis	0.0328	0.0753	CbGbCtD
Pimecrolimus—Paraesthesia—Ibandronate—osteoporosis	0.000544	0.00147	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.000541	0.00146	CcSEcCtD
Pimecrolimus—Pain—Estropipate—osteoporosis	0.00054	0.00146	CcSEcCtD
Pimecrolimus—Constipation—Estropipate—osteoporosis	0.00054	0.00146	CcSEcCtD
Pimecrolimus—Hypersensitivity—Etidronic acid—osteoporosis	0.000538	0.00145	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Estradiol—osteoporosis	0.000536	0.00145	CcSEcCtD
Pimecrolimus—Cough—Risedronate—osteoporosis	0.000534	0.00144	CcSEcCtD
Pimecrolimus—Pain—Alendronate—osteoporosis	0.000532	0.00143	CcSEcCtD
Pimecrolimus—Constipation—Alendronate—osteoporosis	0.000532	0.00143	CcSEcCtD
Pimecrolimus—Angioedema—Pamidronate—osteoporosis	0.000532	0.00143	CcSEcCtD
Pimecrolimus—Erythema—Zoledronate—osteoporosis	0.000531	0.00143	CcSEcCtD
Pimecrolimus—Malnutrition—Zoledronate—osteoporosis	0.000531	0.00143	CcSEcCtD
Pimecrolimus—Immune system disorder—Conjugated Estrogens—osteoporosis	0.000531	0.00143	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000531	0.00143	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.00053	0.00143	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000529	0.00142	CcSEcCtD
Pimecrolimus—Pneumonia—Estradiol—osteoporosis	0.000527	0.00142	CcSEcCtD
Pimecrolimus—Infestation NOS—Estradiol—osteoporosis	0.000524	0.00141	CcSEcCtD
Pimecrolimus—Infestation—Estradiol—osteoporosis	0.000524	0.00141	CcSEcCtD
Pimecrolimus—Pain—Raloxifene—osteoporosis	0.000524	0.00141	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000523	0.00141	CcSEcCtD
Pimecrolimus—Arthralgia—Risedronate—osteoporosis	0.000521	0.0014	CcSEcCtD
Pimecrolimus—Pain—Ibandronate—osteoporosis	0.000518	0.0014	CcSEcCtD
Pimecrolimus—Constipation—Ibandronate—osteoporosis	0.000518	0.0014	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000517	0.00139	CcSEcCtD
Pimecrolimus—Pruritus—Etidronic acid—osteoporosis	0.000517	0.00139	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Estropipate—osteoporosis	0.000517	0.00139	CcSEcCtD
Pimecrolimus—Back pain—Zoledronate—osteoporosis	0.000514	0.00139	CcSEcCtD
Pimecrolimus—Oedema—Ethinyl Estradiol—osteoporosis	0.000512	0.00138	CcSEcCtD
Pimecrolimus—Malnutrition—Conjugated Estrogens—osteoporosis	0.000512	0.00138	CcSEcCtD
Pimecrolimus—Erythema—Conjugated Estrogens—osteoporosis	0.000512	0.00138	CcSEcCtD
Pimecrolimus—Conjunctivitis—Estradiol—osteoporosis	0.000509	0.00137	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Alendronate—osteoporosis	0.000509	0.00137	CcSEcCtD
Pimecrolimus—Infection—Ethinyl Estradiol—osteoporosis	0.000509	0.00137	CcSEcCtD
Pimecrolimus—Cough—Pamidronate—osteoporosis	0.000508	0.00137	CcSEcCtD
Pimecrolimus—Pain—Calcitriol—osteoporosis	0.000507	0.00137	CcSEcCtD
Pimecrolimus—Constipation—Calcitriol—osteoporosis	0.000507	0.00137	CcSEcCtD
Pimecrolimus—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000502	0.00135	CcSEcCtD
Pimecrolimus—Urticaria—Estropipate—osteoporosis	0.000502	0.00135	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Raloxifene—osteoporosis	0.000501	0.00135	CcSEcCtD
Pimecrolimus—Diarrhoea—Etidronic acid—osteoporosis	0.0005	0.00135	CcSEcCtD
Pimecrolimus—Abdominal pain—Estropipate—osteoporosis	0.0005	0.00135	CcSEcCtD
Pimecrolimus—Body temperature increased—Estropipate—osteoporosis	0.0005	0.00135	CcSEcCtD
Pimecrolimus—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000498	0.00134	CcSEcCtD
Pimecrolimus—Infection—Risedronate—osteoporosis	0.000496	0.00134	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Ibandronate—osteoporosis	0.000496	0.00134	CcSEcCtD
Pimecrolimus—Arthralgia—Pamidronate—osteoporosis	0.000495	0.00133	CcSEcCtD
Pimecrolimus—Back pain—Conjugated Estrogens—osteoporosis	0.000495	0.00133	CcSEcCtD
Pimecrolimus—Urticaria—Alendronate—osteoporosis	0.000495	0.00133	CcSEcCtD
Pimecrolimus—Epistaxis—Estradiol—osteoporosis	0.000494	0.00133	CcSEcCtD
Pimecrolimus—Body temperature increased—Alendronate—osteoporosis	0.000492	0.00133	CcSEcCtD
Pimecrolimus—Abdominal pain—Alendronate—osteoporosis	0.000492	0.00133	CcSEcCtD
Pimecrolimus—Sinusitis—Estradiol—osteoporosis	0.000492	0.00132	CcSEcCtD
Pimecrolimus—Nervous system disorder—Risedronate—osteoporosis	0.00049	0.00132	CcSEcCtD
Pimecrolimus—Angioedema—Zoledronate—osteoporosis	0.000486	0.00131	CcSEcCtD
Pimecrolimus—Skin disorder—Risedronate—osteoporosis	0.000485	0.00131	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Calcitriol—osteoporosis	0.000485	0.00131	CcSEcCtD
Pimecrolimus—Body temperature increased—Raloxifene—osteoporosis	0.000484	0.0013	CcSEcCtD
Pimecrolimus—Abdominal pain—Raloxifene—osteoporosis	0.000484	0.0013	CcSEcCtD
Pimecrolimus—Urticaria—Ibandronate—osteoporosis	0.000481	0.0013	CcSEcCtD
Pimecrolimus—Abdominal pain—Ibandronate—osteoporosis	0.000479	0.00129	CcSEcCtD
Pimecrolimus—Body temperature increased—Ibandronate—osteoporosis	0.000479	0.00129	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Pamidronate—osteoporosis	0.000475	0.00128	CcSEcCtD
Pimecrolimus—Oedema—Pamidronate—osteoporosis	0.000475	0.00128	CcSEcCtD
Pimecrolimus—Infection—Pamidronate—osteoporosis	0.000472	0.00127	CcSEcCtD
Pimecrolimus—Rhinitis—Estradiol—osteoporosis	0.000472	0.00127	CcSEcCtD
Pimecrolimus—Urticaria—Calcitriol—osteoporosis	0.000471	0.00127	CcSEcCtD
Pimecrolimus—Abdominal pain—Calcitriol—osteoporosis	0.000469	0.00126	CcSEcCtD
Pimecrolimus—Body temperature increased—Calcitriol—osteoporosis	0.000469	0.00126	CcSEcCtD
Pimecrolimus—Angioedema—Conjugated Estrogens—osteoporosis	0.000468	0.00126	CcSEcCtD
Pimecrolimus—Pharyngitis—Estradiol—osteoporosis	0.000467	0.00126	CcSEcCtD
Pimecrolimus—Hypersensitivity—Estropipate—osteoporosis	0.000466	0.00125	CcSEcCtD
Pimecrolimus—Nervous system disorder—Pamidronate—osteoporosis	0.000466	0.00125	CcSEcCtD
Pimecrolimus—Vomiting—Etidronic acid—osteoporosis	0.000464	0.00125	CcSEcCtD
Pimecrolimus—Cough—Zoledronate—osteoporosis	0.000464	0.00125	CcSEcCtD
Pimecrolimus—Rash—Etidronic acid—osteoporosis	0.000461	0.00124	CcSEcCtD
Pimecrolimus—Dermatitis—Etidronic acid—osteoporosis	0.00046	0.00124	CcSEcCtD
Pimecrolimus—Hypersensitivity—Alendronate—osteoporosis	0.000459	0.00124	CcSEcCtD
Pimecrolimus—Headache—Etidronic acid—osteoporosis	0.000458	0.00123	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000455	0.00123	CcSEcCtD
Pimecrolimus—Arthralgia—Zoledronate—osteoporosis	0.000452	0.00122	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000449	0.00121	CcSEcCtD
Pimecrolimus—Paraesthesia—Risedronate—osteoporosis	0.000448	0.00121	CcSEcCtD
Pimecrolimus—Pruritus—Estropipate—osteoporosis	0.000447	0.0012	CcSEcCtD
Pimecrolimus—Hypersensitivity—Ibandronate—osteoporosis	0.000447	0.0012	CcSEcCtD
Pimecrolimus—Cough—Conjugated Estrogens—osteoporosis	0.000447	0.0012	CcSEcCtD
Pimecrolimus—Dyspnoea—Risedronate—osteoporosis	0.000445	0.0012	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000442	0.00119	CcSEcCtD
Pimecrolimus—Pruritus—Alendronate—osteoporosis	0.00044	0.00119	CcSEcCtD
Pimecrolimus—Eye disorder—Estradiol—osteoporosis	0.00044	0.00118	CcSEcCtD
Pimecrolimus—Constipation—Ethinyl Estradiol—osteoporosis	0.000438	0.00118	CcSEcCtD
Pimecrolimus—Hypersensitivity—Calcitriol—osteoporosis	0.000437	0.00118	CcSEcCtD
Pimecrolimus—Flushing—Estradiol—osteoporosis	0.000437	0.00118	CcSEcCtD
Pimecrolimus—Arthralgia—Conjugated Estrogens—osteoporosis	0.000436	0.00117	CcSEcCtD
Pimecrolimus—Nausea—Etidronic acid—osteoporosis	0.000434	0.00117	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Zoledronate—osteoporosis	0.000434	0.00117	CcSEcCtD
Pimecrolimus—Oedema—Zoledronate—osteoporosis	0.000434	0.00117	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000433	0.00117	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000433	0.00117	CcSEcCtD
Pimecrolimus—Diarrhoea—Estropipate—osteoporosis	0.000432	0.00117	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Risedronate—osteoporosis	0.000431	0.00116	CcSEcCtD
Pimecrolimus—Infection—Zoledronate—osteoporosis	0.000431	0.00116	CcSEcCtD
Pimecrolimus—Pruritus—Ibandronate—osteoporosis	0.000429	0.00116	CcSEcCtD
Pimecrolimus—Constipation—Risedronate—osteoporosis	0.000427	0.00115	CcSEcCtD
Pimecrolimus—Pain—Risedronate—osteoporosis	0.000427	0.00115	CcSEcCtD
Pimecrolimus—Paraesthesia—Pamidronate—osteoporosis	0.000426	0.00115	CcSEcCtD
Pimecrolimus—Diarrhoea—Alendronate—osteoporosis	0.000426	0.00115	CcSEcCtD
Pimecrolimus—Nervous system disorder—Zoledronate—osteoporosis	0.000425	0.00115	CcSEcCtD
Pimecrolimus—Immune system disorder—Estradiol—osteoporosis	0.000425	0.00115	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Estradiol—osteoporosis	0.000424	0.00114	CcSEcCtD
Pimecrolimus—Dyspnoea—Pamidronate—osteoporosis	0.000423	0.00114	CcSEcCtD
Pimecrolimus—Skin disorder—Zoledronate—osteoporosis	0.000421	0.00114	CcSEcCtD
Pimecrolimus—Pruritus—Calcitriol—osteoporosis	0.00042	0.00113	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000419	0.00113	CcSEcCtD
Pimecrolimus—Diarrhoea—Raloxifene—osteoporosis	0.000419	0.00113	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000418	0.00113	CcSEcCtD
Pimecrolimus—Oedema—Conjugated Estrogens—osteoporosis	0.000418	0.00113	CcSEcCtD
Pimecrolimus—Infection—Conjugated Estrogens—osteoporosis	0.000415	0.00112	CcSEcCtD
Pimecrolimus—Diarrhoea—Ibandronate—osteoporosis	0.000415	0.00112	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00041	0.0011	CcSEcCtD
Pimecrolimus—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00041	0.0011	CcSEcCtD
Pimecrolimus—Erythema—Estradiol—osteoporosis	0.00041	0.0011	CcSEcCtD
Pimecrolimus—Malnutrition—Estradiol—osteoporosis	0.00041	0.0011	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Risedronate—osteoporosis	0.000408	0.0011	CcSEcCtD
Pimecrolimus—Urticaria—Ethinyl Estradiol—osteoporosis	0.000407	0.0011	CcSEcCtD
Pimecrolimus—Pain—Pamidronate—osteoporosis	0.000406	0.00109	CcSEcCtD
Pimecrolimus—Constipation—Pamidronate—osteoporosis	0.000406	0.00109	CcSEcCtD
Pimecrolimus—Diarrhoea—Calcitriol—osteoporosis	0.000406	0.00109	CcSEcCtD
Pimecrolimus—Skin disorder—Conjugated Estrogens—osteoporosis	0.000406	0.00109	CcSEcCtD
Pimecrolimus—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000405	0.00109	CcSEcCtD
Pimecrolimus—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000405	0.00109	CcSEcCtD
Pimecrolimus—Vomiting—Estropipate—osteoporosis	0.000402	0.00108	CcSEcCtD
Pimecrolimus—Rash—Estropipate—osteoporosis	0.000398	0.00107	CcSEcCtD
Pimecrolimus—Dermatitis—Estropipate—osteoporosis	0.000398	0.00107	CcSEcCtD
Pimecrolimus—Urticaria—Risedronate—osteoporosis	0.000397	0.00107	CcSEcCtD
Pimecrolimus—Back pain—Estradiol—osteoporosis	0.000396	0.00107	CcSEcCtD
Pimecrolimus—Headache—Estropipate—osteoporosis	0.000396	0.00107	CcSEcCtD
Pimecrolimus—Vomiting—Alendronate—osteoporosis	0.000396	0.00107	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000395	0.00106	CcSEcCtD
Pimecrolimus—Abdominal pain—Risedronate—osteoporosis	0.000395	0.00106	CcSEcCtD
Pimecrolimus—Body temperature increased—Risedronate—osteoporosis	0.000395	0.00106	CcSEcCtD
Pimecrolimus—Rash—Alendronate—osteoporosis	0.000392	0.00106	CcSEcCtD
Pimecrolimus—Dermatitis—Alendronate—osteoporosis	0.000392	0.00106	CcSEcCtD
Pimecrolimus—Headache—Alendronate—osteoporosis	0.00039	0.00105	CcSEcCtD
Pimecrolimus—Paraesthesia—Zoledronate—osteoporosis	0.000389	0.00105	CcSEcCtD
Pimecrolimus—Vomiting—Raloxifene—osteoporosis	0.000389	0.00105	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Pamidronate—osteoporosis	0.000388	0.00105	CcSEcCtD
Pimecrolimus—Dyspnoea—Zoledronate—osteoporosis	0.000387	0.00104	CcSEcCtD
Pimecrolimus—Rash—Raloxifene—osteoporosis	0.000386	0.00104	CcSEcCtD
Pimecrolimus—Dermatitis—Raloxifene—osteoporosis	0.000386	0.00104	CcSEcCtD
Pimecrolimus—Vomiting—Ibandronate—osteoporosis	0.000385	0.00104	CcSEcCtD
Pimecrolimus—Headache—Raloxifene—osteoporosis	0.000384	0.00103	CcSEcCtD
Pimecrolimus—Rash—Ibandronate—osteoporosis	0.000382	0.00103	CcSEcCtD
Pimecrolimus—Dermatitis—Ibandronate—osteoporosis	0.000382	0.00103	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.00038	0.00103	CcSEcCtD
Pimecrolimus—Headache—Ibandronate—osteoporosis	0.00038	0.00102	CcSEcCtD
Pimecrolimus—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000377	0.00102	CcSEcCtD
Pimecrolimus—Vomiting—Calcitriol—osteoporosis	0.000377	0.00102	CcSEcCtD
Pimecrolimus—Nausea—Estropipate—osteoporosis	0.000375	0.00101	CcSEcCtD
Pimecrolimus—Abdominal pain—Pamidronate—osteoporosis	0.000375	0.00101	CcSEcCtD
Pimecrolimus—Body temperature increased—Pamidronate—osteoporosis	0.000375	0.00101	CcSEcCtD
Pimecrolimus—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000375	0.00101	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000374	0.00101	CcSEcCtD
Pimecrolimus—Angioedema—Estradiol—osteoporosis	0.000374	0.00101	CcSEcCtD
Pimecrolimus—Rash—Calcitriol—osteoporosis	0.000374	0.00101	CcSEcCtD
Pimecrolimus—Dermatitis—Calcitriol—osteoporosis	0.000374	0.00101	CcSEcCtD
Pimecrolimus—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000372	0.001	CcSEcCtD
Pimecrolimus—Headache—Calcitriol—osteoporosis	0.000372	0.001	CcSEcCtD
Pimecrolimus—Pain—Zoledronate—osteoporosis	0.000371	0.000999	CcSEcCtD
Pimecrolimus—Constipation—Zoledronate—osteoporosis	0.000371	0.000999	CcSEcCtD
Pimecrolimus—Nausea—Alendronate—osteoporosis	0.00037	0.000996	CcSEcCtD
Pimecrolimus—Hypersensitivity—Risedronate—osteoporosis	0.000368	0.000992	CcSEcCtD
Pimecrolimus—Nausea—Raloxifene—osteoporosis	0.000364	0.00098	CcSEcCtD
Pimecrolimus—Pruritus—Ethinyl Estradiol—osteoporosis	0.000362	0.000977	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000361	0.000972	CcSEcCtD
Pimecrolimus—Nausea—Ibandronate—osteoporosis	0.00036	0.00097	CcSEcCtD
Pimecrolimus—Cough—Estradiol—osteoporosis	0.000357	0.000963	CcSEcCtD
Pimecrolimus—Constipation—Conjugated Estrogens—osteoporosis	0.000357	0.000962	CcSEcCtD
Pimecrolimus—Pain—Conjugated Estrogens—osteoporosis	0.000357	0.000962	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Zoledronate—osteoporosis	0.000355	0.000956	CcSEcCtD
Pimecrolimus—Pruritus—Risedronate—osteoporosis	0.000353	0.000952	CcSEcCtD
Pimecrolimus—Nausea—Calcitriol—osteoporosis	0.000352	0.00095	CcSEcCtD
Pimecrolimus—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000351	0.000945	CcSEcCtD
Pimecrolimus—Hypersensitivity—Pamidronate—osteoporosis	0.00035	0.000943	CcSEcCtD
Pimecrolimus—Arthralgia—Estradiol—osteoporosis	0.000349	0.00094	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000346	0.000933	CcSEcCtD
Pimecrolimus—Urticaria—Zoledronate—osteoporosis	0.000345	0.000928	CcSEcCtD
Pimecrolimus—Abdominal pain—Zoledronate—osteoporosis	0.000343	0.000924	CcSEcCtD
Pimecrolimus—Body temperature increased—Zoledronate—osteoporosis	0.000343	0.000924	CcSEcCtD
Pimecrolimus—Diarrhoea—Risedronate—osteoporosis	0.000342	0.000921	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000341	0.00092	CcSEcCtD
Pimecrolimus—Pruritus—Pamidronate—osteoporosis	0.000336	0.000905	CcSEcCtD
Pimecrolimus—Oedema—Estradiol—osteoporosis	0.000334	0.000901	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Estradiol—osteoporosis	0.000334	0.000901	CcSEcCtD
Pimecrolimus—Infection—Estradiol—osteoporosis	0.000332	0.000895	CcSEcCtD
Pimecrolimus—Urticaria—Conjugated Estrogens—osteoporosis	0.000332	0.000894	CcSEcCtD
Pimecrolimus—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00033	0.00089	CcSEcCtD
Pimecrolimus—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00033	0.00089	CcSEcCtD
Pimecrolimus—Nervous system disorder—Estradiol—osteoporosis	0.000328	0.000883	CcSEcCtD
Pimecrolimus—Vomiting—Ethinyl Estradiol—osteoporosis	0.000326	0.000878	CcSEcCtD
Pimecrolimus—Diarrhoea—Pamidronate—osteoporosis	0.000325	0.000875	CcSEcCtD
Pimecrolimus—Skin disorder—Estradiol—osteoporosis	0.000325	0.000875	CcSEcCtD
Pimecrolimus—Rash—Ethinyl Estradiol—osteoporosis	0.000323	0.00087	CcSEcCtD
Pimecrolimus—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000323	0.00087	CcSEcCtD
Pimecrolimus—Headache—Ethinyl Estradiol—osteoporosis	0.000321	0.000865	CcSEcCtD
Pimecrolimus—Hypersensitivity—Zoledronate—osteoporosis	0.00032	0.000861	CcSEcCtD
Pimecrolimus—Vomiting—Risedronate—osteoporosis	0.000318	0.000856	CcSEcCtD
Pimecrolimus—Rash—Risedronate—osteoporosis	0.000315	0.000849	CcSEcCtD
Pimecrolimus—Dermatitis—Risedronate—osteoporosis	0.000315	0.000848	CcSEcCtD
Pimecrolimus—Headache—Risedronate—osteoporosis	0.000313	0.000843	CcSEcCtD
Pimecrolimus—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000308	0.000829	CcSEcCtD
Pimecrolimus—Pruritus—Zoledronate—osteoporosis	0.000307	0.000827	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000305	0.000821	CcSEcCtD
Pimecrolimus—Nausea—Ethinyl Estradiol—osteoporosis	0.000304	0.00082	CcSEcCtD
Pimecrolimus—Vomiting—Pamidronate—osteoporosis	0.000302	0.000813	CcSEcCtD
Pimecrolimus—Paraesthesia—Estradiol—osteoporosis	0.0003	0.000809	CcSEcCtD
Pimecrolimus—Rash—Pamidronate—osteoporosis	0.000299	0.000807	CcSEcCtD
Pimecrolimus—Dermatitis—Pamidronate—osteoporosis	0.000299	0.000806	CcSEcCtD
Pimecrolimus—Dyspnoea—Estradiol—osteoporosis	0.000298	0.000803	CcSEcCtD
Pimecrolimus—Headache—Pamidronate—osteoporosis	0.000297	0.000802	CcSEcCtD
Pimecrolimus—Diarrhoea—Zoledronate—osteoporosis	0.000297	0.0008	CcSEcCtD
Pimecrolimus—Nausea—Risedronate—osteoporosis	0.000297	0.000799	CcSEcCtD
Pimecrolimus—Pruritus—Conjugated Estrogens—osteoporosis	0.000295	0.000796	CcSEcCtD
Pimecrolimus—MTOR—Disease—PKM—osteoporosis	0.000292	0.00151	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SOST—osteoporosis	0.000292	0.00151	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ACP5—osteoporosis	0.00029	0.0015	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Estradiol—osteoporosis	0.000289	0.000778	CcSEcCtD
Pimecrolimus—Constipation—Estradiol—osteoporosis	0.000286	0.00077	CcSEcCtD
Pimecrolimus—Pain—Estradiol—osteoporosis	0.000286	0.00077	CcSEcCtD
Pimecrolimus—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000286	0.00077	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—osteoporosis	0.000285	0.00147	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—IRS1—osteoporosis	0.000285	0.00147	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IRS1—osteoporosis	0.000284	0.00146	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6R—osteoporosis	0.000283	0.00146	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IRS1—osteoporosis	0.000282	0.00146	CbGpPWpGaD
Pimecrolimus—Nausea—Pamidronate—osteoporosis	0.000282	0.00076	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—IRS1—osteoporosis	0.000281	0.00145	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IRS1—osteoporosis	0.000279	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6R—osteoporosis	0.000279	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—IRS2—osteoporosis	0.000279	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PGLS—osteoporosis	0.000277	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ANTXR2—osteoporosis	0.000277	0.00143	CbGpPWpGaD
Pimecrolimus—Vomiting—Zoledronate—osteoporosis	0.000276	0.000743	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—IRS1—osteoporosis	0.000275	0.00142	CbGpPWpGaD
Pimecrolimus—Rash—Zoledronate—osteoporosis	0.000273	0.000737	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Estradiol—osteoporosis	0.000273	0.000736	CcSEcCtD
Pimecrolimus—Dermatitis—Zoledronate—osteoporosis	0.000273	0.000736	CcSEcCtD
Pimecrolimus—Headache—Zoledronate—osteoporosis	0.000272	0.000732	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL6—osteoporosis	0.000271	0.0014	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TPI1—osteoporosis	0.000269	0.00139	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IRS2—osteoporosis	0.000267	0.00138	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6R—osteoporosis	0.000266	0.00138	CbGpPWpGaD
Pimecrolimus—Vomiting—Conjugated Estrogens—osteoporosis	0.000266	0.000715	CcSEcCtD
Pimecrolimus—Urticaria—Estradiol—osteoporosis	0.000266	0.000715	CcSEcCtD
Pimecrolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000265	0.00137	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6R—osteoporosis	0.000265	0.00137	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—osteoporosis	0.000265	0.00137	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Estradiol—osteoporosis	0.000264	0.000712	CcSEcCtD
Pimecrolimus—Abdominal pain—Estradiol—osteoporosis	0.000264	0.000712	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6R—osteoporosis	0.000264	0.00136	CbGpPWpGaD
Pimecrolimus—Rash—Conjugated Estrogens—osteoporosis	0.000263	0.00071	CcSEcCtD
Pimecrolimus—Dermatitis—Conjugated Estrogens—osteoporosis	0.000263	0.000709	CcSEcCtD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IRS1—osteoporosis	0.000263	0.00136	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IRS1—osteoporosis	0.000263	0.00136	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IRS1—osteoporosis	0.000263	0.00136	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6R—osteoporosis	0.000262	0.00136	CbGpPWpGaD
Pimecrolimus—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000262	0.00135	CbGpPWpGaD
Pimecrolimus—Headache—Conjugated Estrogens—osteoporosis	0.000262	0.000705	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—SOD2—osteoporosis	0.000261	0.00135	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MGLL—osteoporosis	0.000261	0.00135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IRS1—osteoporosis	0.000261	0.00135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IRS1—osteoporosis	0.000258	0.00133	CbGpPWpGaD
Pimecrolimus—Nausea—Zoledronate—osteoporosis	0.000258	0.000694	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—IRS1—osteoporosis	0.000257	0.00133	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LRP5—osteoporosis	0.000255	0.00131	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—P4HB—osteoporosis	0.000253	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CTSK—osteoporosis	0.000251	0.0013	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—GPX1—osteoporosis	0.000249	0.00129	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—GAPDH—osteoporosis	0.000249	0.00128	CbGpPWpGaD
Pimecrolimus—Nausea—Conjugated Estrogens—osteoporosis	0.000248	0.000668	CcSEcCtD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—osteoporosis	0.000247	0.00128	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NFATC1—osteoporosis	0.000247	0.00128	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6R—osteoporosis	0.000247	0.00127	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6R—osteoporosis	0.000247	0.00127	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6R—osteoporosis	0.000247	0.00127	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Estradiol—osteoporosis	0.000246	0.000664	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	0.000245	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6R—osteoporosis	0.000245	0.00126	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	0.000244	0.00126	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LRP6—osteoporosis	0.000244	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—IRS1—osteoporosis	0.000243	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—RAP1A—osteoporosis	0.000243	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6R—osteoporosis	0.000243	0.00125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6R—osteoporosis	0.000241	0.00125	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CTSK—osteoporosis	0.000241	0.00124	CbGpPWpGaD
Pimecrolimus—Pruritus—Estradiol—osteoporosis	0.000236	0.000637	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—NFATC1—osteoporosis	0.000236	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—GSN—osteoporosis	0.000235	0.00121	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—ADCY5—osteoporosis	0.000234	0.00121	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—DKK1—osteoporosis	0.000234	0.00121	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IRS1—osteoporosis	0.000233	0.0012	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Estradiol—osteoporosis	0.000229	0.000616	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	0.000228	0.00118	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—WNT1—osteoporosis	0.000226	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—osteoporosis	0.000222	0.00114	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGA—osteoporosis	0.00022	0.00113	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6R—osteoporosis	0.000219	0.00113	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	0.000218	0.00112	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000215	0.00111	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	0.000215	0.00111	CbGpPWpGaD
Pimecrolimus—Vomiting—Estradiol—osteoporosis	0.000213	0.000573	CcSEcCtD
Pimecrolimus—Rash—Estradiol—osteoporosis	0.000211	0.000568	CcSEcCtD
Pimecrolimus—Dermatitis—Estradiol—osteoporosis	0.000211	0.000567	CcSEcCtD
Pimecrolimus—Headache—Estradiol—osteoporosis	0.000209	0.000564	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—TLN1—osteoporosis	0.000206	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IRS2—osteoporosis	0.000205	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—LRP5—osteoporosis	0.000205	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SOST—osteoporosis	0.000204	0.00105	CbGpPWpGaD
Pimecrolimus—Nausea—Estradiol—osteoporosis	0.000199	0.000535	CcSEcCtD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—osteoporosis	0.000198	0.00102	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ENO1—osteoporosis	0.000196	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—LRP6—osteoporosis	0.000196	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PSMA2—osteoporosis	0.000194	0.001	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PSMA5—osteoporosis	0.000194	0.001	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRAK3—osteoporosis	0.000193	0.000996	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PSMA2—osteoporosis	0.000193	0.000996	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PSMA5—osteoporosis	0.000193	0.000996	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—IL6—osteoporosis	0.000192	0.000993	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—osteoporosis	0.000191	0.000984	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RPL24—osteoporosis	0.000188	0.00097	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—LTF—osteoporosis	0.000188	0.00097	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—osteoporosis	0.000186	0.000959	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—osteoporosis	0.000186	0.000959	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTH1R—osteoporosis	0.000185	0.000954	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CALCR—osteoporosis	0.000185	0.000954	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CALCA—osteoporosis	0.00018	0.000928	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IRS1—osteoporosis	0.000179	0.000925	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—P4HB—osteoporosis	0.000177	0.000916	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ACTG1—osteoporosis	0.000177	0.000911	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTH—osteoporosis	0.000173	0.000891	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KL—osteoporosis	0.000171	0.000881	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RAP1A—osteoporosis	0.00017	0.000875	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6R—osteoporosis	0.000168	0.000868	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CNR2—osteoporosis	0.000168	0.000868	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—osteoporosis	0.000167	0.000862	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MYC—osteoporosis	0.000166	0.000858	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NFATC1—osteoporosis	0.000165	0.000854	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—osteoporosis	0.000165	0.000849	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—DKK1—osteoporosis	0.000164	0.000847	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KL—osteoporosis	0.000164	0.000846	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KL—osteoporosis	0.000163	0.000843	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ACP5—osteoporosis	0.000163	0.000841	CbGpPWpGaD
Pimecrolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.00016	0.000824	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—WNT1—osteoporosis	0.000158	0.000816	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—osteoporosis	0.000155	0.000802	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—osteoporosis	0.000154	0.000796	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGA—osteoporosis	0.000154	0.000794	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TPI1—osteoporosis	0.000152	0.000782	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RAP1A—osteoporosis	0.000148	0.000762	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MGLL—osteoporosis	0.000147	0.000758	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTSK—osteoporosis	0.000146	0.000755	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NFATC1—osteoporosis	0.000144	0.000743	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LRP5—osteoporosis	0.000143	0.00074	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTHLH—osteoporosis	0.000143	0.000738	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—BMP2—osteoporosis	0.000143	0.000738	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—P4HB—osteoporosis	0.000142	0.000735	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGB—osteoporosis	0.00014	0.000722	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—GAPDH—osteoporosis	0.00014	0.000722	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LRP6—osteoporosis	0.000137	0.000707	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PSMA2—osteoporosis	0.000135	0.000697	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PSMA5—osteoporosis	0.000135	0.000697	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AGER—osteoporosis	0.000134	0.000693	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ADCY5—osteoporosis	0.000134	0.00069	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NFATC1—osteoporosis	0.000133	0.000686	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—osteoporosis	0.000132	0.000681	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—DKK1—osteoporosis	0.000132	0.00068	CbGpPWpGaD
Pimecrolimus—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000129	0.000668	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ADCY5—osteoporosis	0.000128	0.00066	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—WNT1—osteoporosis	0.000127	0.000656	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—osteoporosis	0.000126	0.000652	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CALCA—osteoporosis	0.000126	0.00065	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—osteoporosis	0.000124	0.000641	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGA—osteoporosis	0.000124	0.000638	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—osteoporosis	0.000119	0.000613	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—osteoporosis	0.000118	0.00061	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTHFR—osteoporosis	0.000118	0.000607	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—osteoporosis	0.000117	0.000607	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PSMA5—osteoporosis	0.000117	0.000607	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PSMA2—osteoporosis	0.000117	0.000607	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IRS2—osteoporosis	0.000117	0.000604	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—osteoporosis	0.000117	0.000604	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TLN1—osteoporosis	0.000116	0.000597	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	0.000114	0.00059	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KL—osteoporosis	0.000114	0.00059	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	0.000113	0.000582	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—IRS2—osteoporosis	0.000112	0.00058	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IRS2—osteoporosis	0.000112	0.000578	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ENO1—osteoporosis	0.00011	0.000568	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—osteoporosis	0.00011	0.000568	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—osteoporosis	0.00011	0.000568	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	0.00011	0.000568	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—osteoporosis	0.000109	0.000563	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PSMA5—osteoporosis	0.000108	0.00056	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PSMA2—osteoporosis	0.000108	0.00056	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—osteoporosis	0.000108	0.000558	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—osteoporosis	0.000108	0.000555	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IRS1—osteoporosis	0.000102	0.000527	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CALCA—osteoporosis	0.000101	0.000522	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—P4HB—osteoporosis	9.98e-05	0.000515	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KL—osteoporosis	9.94e-05	0.000513	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—IRS1—osteoporosis	9.81e-05	0.000506	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IRS1—osteoporosis	9.77e-05	0.000504	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	9.74e-05	0.000503	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTH—osteoporosis	9.7e-05	0.000501	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6R—osteoporosis	9.59e-05	0.000495	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RAP1A—osteoporosis	9.54e-05	0.000492	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CNR2—osteoporosis	9.46e-05	0.000488	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NFATC1—osteoporosis	9.3e-05	0.00048	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DKK1—osteoporosis	9.23e-05	0.000477	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KL—osteoporosis	9.18e-05	0.000474	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6R—osteoporosis	9.17e-05	0.000474	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADCY5—osteoporosis	8.95e-05	0.000462	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—WNT1—osteoporosis	8.89e-05	0.000459	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SPP1—osteoporosis	8.66e-05	0.000447	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGA—osteoporosis	8.65e-05	0.000447	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTHLH—osteoporosis	8.04e-05	0.000415	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BMP2—osteoporosis	8.04e-05	0.000415	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—osteoporosis	7.99e-05	0.000412	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGB—osteoporosis	7.87e-05	0.000406	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IRS2—osteoporosis	7.83e-05	0.000404	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AGER—osteoporosis	7.82e-05	0.000403	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ADCY5—osteoporosis	7.79e-05	0.000402	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LEP—osteoporosis	7.67e-05	0.000396	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PSMA2—osteoporosis	7.6e-05	0.000392	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PSMA5—osteoporosis	7.6e-05	0.000392	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—osteoporosis	7.49e-05	0.000387	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ESR1—osteoporosis	7.32e-05	0.000378	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ADCY5—osteoporosis	7.19e-05	0.000371	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CALCA—osteoporosis	7.08e-05	0.000365	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—POMC—osteoporosis	6.87e-05	0.000355	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IRS1—osteoporosis	6.84e-05	0.000353	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRS2—osteoporosis	6.81e-05	0.000352	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—osteoporosis	6.61e-05	0.000341	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—POMC—osteoporosis	6.59e-05	0.00034	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PKM—osteoporosis	6.48e-05	0.000335	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FDPS—osteoporosis	6.48e-05	0.000335	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KL—osteoporosis	6.43e-05	0.000332	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6R—osteoporosis	6.42e-05	0.000332	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF1—osteoporosis	6.33e-05	0.000327	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IRS2—osteoporosis	6.29e-05	0.000325	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPD2—osteoporosis	6.14e-05	0.000317	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PGLS—osteoporosis	6.14e-05	0.000317	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRS1—osteoporosis	5.95e-05	0.000307	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ATIC—osteoporosis	5.62e-05	0.00029	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PNP—osteoporosis	5.62e-05	0.00029	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6R—osteoporosis	5.59e-05	0.000289	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IRS1—osteoporosis	5.49e-05	0.000284	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—osteoporosis	5.44e-05	0.000281	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—osteoporosis	5.42e-05	0.00028	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6R—osteoporosis	5.16e-05	0.000266	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADCY5—osteoporosis	5.04e-05	0.00026	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SPP1—osteoporosis	4.87e-05	0.000252	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CA2—osteoporosis	4.78e-05	0.000247	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—OXCT1—osteoporosis	4.78e-05	0.000247	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MGLL—osteoporosis	4.66e-05	0.00024	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IRS2—osteoporosis	4.41e-05	0.000227	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LEP—osteoporosis	4.31e-05	0.000223	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—osteoporosis	4.27e-05	0.000221	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—osteoporosis	4.25e-05	0.000219	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ESR1—osteoporosis	4.12e-05	0.000213	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—osteoporosis	4.09e-05	0.000211	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—IDH2—osteoporosis	3.96e-05	0.000204	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IRS1—osteoporosis	3.85e-05	0.000199	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—osteoporosis	3.81e-05	0.000197	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—osteoporosis	3.8e-05	0.000196	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.72e-05	0.000192	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—POMC—osteoporosis	3.7e-05	0.000191	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ACP5—osteoporosis	3.62e-05	0.000187	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6R—osteoporosis	3.61e-05	0.000187	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1—osteoporosis	3.56e-05	0.000184	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TPI1—osteoporosis	3.37e-05	0.000174	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—P4HB—osteoporosis	3.16e-05	0.000163	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GAPDH—osteoporosis	3.11e-05	0.00016	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—osteoporosis	3.06e-05	0.000158	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—osteoporosis	3.05e-05	0.000157	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—RAP1A—osteoporosis	3.03e-05	0.000156	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—osteoporosis	2.86e-05	0.000148	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—osteoporosis	2.49e-05	0.000129	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENO1—osteoporosis	2.45e-05	0.000126	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PSMA2—osteoporosis	2.41e-05	0.000124	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PSMA5—osteoporosis	2.41e-05	0.000124	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—osteoporosis	2.3e-05	0.000119	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—osteoporosis	2.14e-05	0.000111	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—osteoporosis	2.14e-05	0.00011	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.95e-05	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—osteoporosis	1.61e-05	8.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADCY5—osteoporosis	1.6e-05	8.25e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX1—osteoporosis	1.59e-05	8.22e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—osteoporosis	1.47e-05	7.58e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—POMC—osteoporosis	1.17e-05	6.07e-05	CbGpPWpGaD
